Transaction in Own Shares

RNS Number : 5456Q

PureTech Health PLC

29 June 2022

 

29 June 2022

PureTech Health plc

Transaction in Own Shares

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

Date of purchase:	28 June 2022
Number of ordinary shares purchased:	3,432
Highest price paid per share:	171.60p
Lowest price paid per share:	171.60p
Volume weighted average price paid per share:	171.60p

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 1,737,780 ordinary shares in treasury and has 286,873,340 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 286,873,340, which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules. 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders.

This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 27 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization, as of the date of PureTech's most recently filed Annual Report and corresponding Form 6-K. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on unique insights in immunology and drug development.

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Contact:

PureTech

Investor Relations

[e-mail]

Individual Transactions

Transaction Date	Transaction Time	Volume	Price (GBp)	Platform	Transaction Reference Number
28/06/2022	16:29:44	108	171.6	XLON	00307483464TRLO1.1.1
28/06/2022	16:29:44	243	171.6	XLON	00307483462TRLO1.1.1
28/06/2022	16:29:44	33	171.6	XLON	00307483459TRLO1.1.1
28/06/2022	16:29:44	198	171.6	XLON	00307483429TRLO1.1.1
28/06/2022	16:29:44	464	171.6	XLON	00307483430TRLO1.1.1
28/06/2022	15:32:55	32	171.6	XLON	00307453417TRLO1.1.1
28/06/2022	15:13:25	52	171.6	AQXE	00307443713TRLO1.1.1
28/06/2022	15:13:25	58	171.6	AQXE	00307443711TRLO1.1.1
28/06/2022	15:13:25	56	171.6	AQXE	00307443709TRLO1.1.1
28/06/2022	15:13:25	59	171.6	AQXE	00307443707TRLO1.1.1
28/06/2022	15:13:25	60	171.6	AQXE	00307443705TRLO1.1.1
28/06/2022	15:13:25	58	171.6	AQXE	00307443703TRLO1.1.1
28/06/2022	15:13:25	66	171.6	AQXE	00307443701TRLO1.1.1
28/06/2022	15:13:25	58	171.6	AQXE	00307443699TRLO1.1.1
28/06/2022	15:13:25	57	171.6	AQXE	00307443697TRLO1.1.1
28/06/2022	15:13:25	60	171.6	AQXE	00307443695TRLO1.1.1
28/06/2022	15:13:25	55	171.6	AQXE	00307443693TRLO1.1.1
28/06/2022	15:13:25	55	171.6	AQXE	00307443690TRLO1.1.1
28/06/2022	15:13:25	55	171.6	AQXE	00307443688TRLO1.1.1
28/06/2022	15:13:25	55	171.6	AQXE	00307443686TRLO1.1.1
28/06/2022	14:45:16	377	171.6	XLON	00307427534TRLO1.1.1
28/06/2022	14:45:16	47	171.6	XLON	00307427529TRLO1.1.1
28/06/2022	13:00:15	53	171.6	XLON	00307389673TRLO1.1.1
28/06/2022	13:00:15	236	171.6	XLON	00307389671TRLO1.1.1
28/06/2022	12:43:04	110	171.6	XLON	00307384195TRLO1.1.1
28/06/2022	09:57:40	79	171.6	XLON	00307312365TRLO1.1.1
28/06/2022	08:43:20	242	171.6	XLON	00307274031TRLO1.1.1
28/06/2022	08:29:36	74	171.6	XLON	00307264129TRLO1.1.1
28/06/2022	08:18:39	105	171.6	XLON	00307256199TRLO1.1.1
28/06/2022	08:10:00	227	171.6	XLON	00307249707TRLO1.1.1

 

END

 

 

POSFLFSDRIITFIF